PETVIVO ANNOUNCES RELEASE OF TWO REASEARCH ABSTRACTS AND UPCOMING CONFERENCE PRESENTATIONS ON OSTEOARTHRITIS IN RHESUS MACAQUESGlobeNewsWire · Oct 15, 2026
Michael Handley Joins PetVivo Holdings, Inc. Board of DirectorsGlobeNewsWire · Sep 22, 2026
Jaime Pickett Joins PetVivo Holdings, Inc. Board of DirectorsGlobeNewsWire · Sep 22, 2026
PETVIVO ANIMAL HEALTH, INC. RELEASES CONFERENCE AND EXHIBIT SCHEDULE FOR 2026-2027GlobeNewsWire · Sep 16, 2026
PETVIVO HOLDINGS ANNOUNCES NAME CHANGE OF HUMAN SUBSIDIARY TO SOMATRIX TECHNOLOGIES, INC. AND EXPANDS FOCUS ON HUMAN HEALTH INNOVATIONGlobe News Wire · Aug 20, 2026
PetVivo Holdings, Inc. (PETV) Q1 2027 Earnings Call TranscriptSeeking Alpha · Aug 14, 2026PetVivo Holdings, Inc. operates as a biomedical technology firm, specializing in the invention, commercialization, and licensing of advanced medical devices and biomaterials intended to treat a variety of ailments and diseases affecting animals. Its flagship product is Spryng, an intra-articular injection administered by veterinarians to effectively alleviate lameness and joint conditions, such as osteoarthritis, in canines and equines. The company's development pipeline further includes seventeen therapeutic devices poised for both veterinary and human clinical applications.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 14, 2026 | -$0.08 | -$0.05 | Beat |
| Jun 29, 2026 | – | -$0.11 | |
| Feb 17, 2026 | – | -$0.07 | |
| Nov 14, 2025 | – | -$0.11 | |
| Aug 14, 2025 | – | -$0.09 | |
| Jun 30, 2025 | – | -$0.12 |